On April 15, 2020, MicroPort^® Scientific Corporation (Stock code: 00853) ("MicroPort^®"), announced that MicroPort^® CardioFlow ("MicroPort^® CardioFlow"), which is a subsidiary of MicroPort^®, had completed raising a new round of funds on the basis of a pre-money valuation of US$1.1 billion. The introduction of seven prominent strategic investors, who are CPE, Hillhouse Capital Management, Ltd., Lake Bleu Capital, Gamnat, China Reform Conson Soochow Overseas Fund I L.P., Gortune Artemis Limited, and 3H Health Investment Fund I, L.P., raised approximately US$130 million. After this round of fundraising, the investors will have an aggregate shareholding of 10.83% in MicroPort^® CardioFlow. J.P. Morgan Securities (Asia Pacific) Limited and Citigroup Global Markets Asia Limited acted as co-placement agents in the transaction.

On September 19, 2019, the first post-marketing implantation of the VitaFlow^® Valve System and Alwide^® Balloon in Lingnan Region was successfully performed by the team of Prof. Luo Jianfang at Guangdong General Hospital.

Shanghai, China - on August 28, 2019, the first implantation of the self-developed VitaFlow^® Transcatheter Aortic Valve System of MicroPort^® Cardioflow was performed at Zhongshan Hospital affiliated to Fudan University. Prof. Ge Junbo, Academician of Chinese Academy of Sciences, Director of the Cardiology Department of Zhongshan Hospital, performed the surgery and successfully implanted the VitaFlow^® aortic valve into a 70-year-old male patient.